AbCellera Biologics ($ABCL) Insider Trading & Smart Money Activity
AbCellera Biologics Inc. ($ABCL) has 3 insider trades and 13 13F position changes on file. Insiders filed 3 Form 4 transactions in the last 12 months, none of them open-market purchases or sales.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- $0
- Congress trades (12 mo)
- 0
- 13F moves on file
- 13
- Analyst ratings on file
- 0
ABCL insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 8 / 4 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 1 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ABCL insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 13F | Counterpoint Mutual Funds | Sold out | -971.64K sh | — | |||||||
| Insider | Stephen Quake | Buy (Grant or award) | 111.70K sh | +4.9% | +23.7% | — | |||||
| Insider | John Montalbano | Buy (Grant or award) | 111.70K sh | +4.9% | +23.7% | — | |||||
| Insider | Michael Hayden | Buy (Grant or award) | 111.70K sh | +4.9% | +23.7% | — | |||||
| 13F | Two Sigma Investments | Added | +4.75M sh | $56.40M | +27.1% | +28.6% | — | ||||
| 13F | Two Sigma Investments | Added | +4.75M sh | $84.65M | +27.1% | +28.6% | — | ||||
| 13F | Two Sigma Advisers | Sold out | -4.88M sh | +27.1% | +28.6% | — | |||||
| 13F | Two Sigma Advisers | Sold out | -4.88M sh | +27.1% | +28.6% | — | |||||
| 13F | Tudor Investment | Added | +477.48K sh | $18.22M | +27.1% | +28.6% | Read | ||||
| 13F | Baker Bros. Advisors | Added | +2.75M sh | $242.66M | +27.1% | +28.6% | — | ||||
| 13F | Simplex Trading | New | +201.24K sh | $1.07M | +16.8% | +19.5% | — | ||||
| 13F | Simplex Trading | New | +201.24K sh | $1.61M | +16.8% | +19.5% | — | ||||
| 13F | Group One Trading | Added | +110.13K sh | $1.28M | -4.2% | +9.9% | — | ||||
| 13F | Group One Trading | Added | +110.13K sh | $1.92M | -4.2% | +9.9% | — | ||||
| 13F | Dekabank Deutsche Girozentrale | Sold out | -87K sh | -8.7% | +12.4% | — | |||||
| 13F | Dekabank Deutsche Girozentrale | Sold out | -87K sh | -8.7% | +12.4% | — |
1W / 1M / 6M = how ABCL moved from the trade or filing date.
Insider trading in ABCL: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Stephen Quake | 1 | — | Jun 11, 2026 | ||
| John Montalbano | 1 | — | Jun 11, 2026 | ||
| Michael Hayden | 1 | — | Jun 11, 2026 |
Institutions moving ABCL (13F)
Frequently asked questions
What is the latest insider trade in ABCL?
Stephen Quake filed a buy (grant or award) of 111.70K sh on Jun 11, 2026.
Which institutions changed their ABCL positions?
Recent 13F filers moving the stock include Two Sigma Investments, Two Sigma Advisers, Simplex Trading, Group One Trading and Dekabank Deutsche Girozentrale.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.